SEARCH

SEARCH BY CITATION

References

  • 1
    Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005; 8: 39.
  • 2
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 133941.
  • 3
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 11727.
  • 4
    van den Hout WB, Bremander A, Vliet Vlieland TP. Recommendations for economic evaluations of non-pharmacological arthritis care: results from the CARE VI meeting 2010. Musculoskelet Care 2011; 9: 1203.
  • 5
    Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics 2009; 27: 71323.
  • 6
    Brown MM, Brown GC. Update on value-based medicine. Curr Opin Ophthalmol 2013; 24: 1839.
  • 7
    Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res (Hoboken) 2011; 63(Suppl. 11): S383412.
  • 8
    Kharroubi SA, Brazier JE, Roberts J, O'Hagan A. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ 2007; 26: 597612.
  • 9
    Dan AA, Kallman JB, Srivastava R, Younoszai Z, Kim A, Younossi ZM. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl 2008; 14: 3216.
  • 10
    Dolan P. Modelling valuations in EuroQol health states. Med Care 1997; 35: 1095108.
  • 11
    Wolowacz S, Petrillo J, Doward L, Briggs A. Measuring Utility for Economic Models Within Clinical Trials: Can we do Better? ISPOR 16th Annual European Congress, Issue Panel 3, 2013 Ireland, Dublin.
  • 12
    Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a Mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008; 11: 113143.
  • 13
    Richardson J, Khan MA, Iezzi A, Maxwell A. Cross-national comparison of twelve quality of life instruments: MIC paper 3 United Kingdom. November, 2012. Clayton, Vic., Australia: Centre for Health Economics, Monash University.
  • 14
    Rowen D, Brazier J, Tsuchiya A, Alava MH. Valuing states from multiple measures on the same visual analogue scale: a feasibility study. Health Econ 2012; 21: 71529.
  • 15
    Gray A, Clarke P, Rivero-Arias O. Estimating the association between SF-36 responses and EQ-5D utility values by direct mapping. Proceedings of Health Economists Study Group Meeting (HESG) (January 2004, Paris, France), paper H8, 2004, pp. 118.
  • 16
    Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009; 31: 27.
  • 17
    Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 55362.
  • 18
    Mathis AS. Economic burden and current managed care challenges associated with hepatitis C. Am J Manag Care 2012; 18(14 Suppl.): S3509.
  • 19
    Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care 2011; 17: 65764.
  • 20
    Camma C, Petta S, Cabibbo G, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol 2013; 59: 65866.
  • 21
    Chan K, Lai MN, Groessl EJ, et al. Cost-effectiveness analysis of direct-acting antiviral therapy for treatment-naive patients with chronic hepatitis C genotype 1 infection in the Veterans health administration. Clin Gastroenterol Hepatol. 2013; 11: 150310.
  • 22
    Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. Transpl Int 2013; 26: 52734.
  • 23
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 24
    Marcellin P, Chousterman M, Fontanges T, et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011; 31: 51624.
  • 25
    McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292303.
  • 26
    Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 101424.
  • 27
    Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 33543.
  • 28
    Vera-Llonch M, Martin M, Aggarwal J, et al. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013; 38: 12433.
  • 29
    Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 187887.
  • 30
    Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 186777.
  • 31
    Younossi ZM, Stepanova M, Mir HM, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2013; 58: S557.
  • 32
    Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013. doi:pii: S1542-3565(13)01838-7. doi: 10.1016/j.cgh.2013.11.032
  • 33
    Miller MH, Agarwal K, Austin A, et al. Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014. doi:10.1111/apt.12764
  • 34
    Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 47887. doi:10.1111/apt.12601
  • 35
    Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003; 11: 4.
  • 36
    Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis c treated with sofosbuvir and ribavirin: the VALENCE Study. J Hepatol 2014. pii: S0168-8278(14)00220-7. doi: 10.1016/j.jhep.2014.04.003
  • 37
    Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014 59: 21619.
  • 38
    Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 14957.
  • 39
    Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat 2013; 20: 5505.